Navigation Links
Jennerex Reports Positive Phase 1 Results for JX-594 Administered Intravenously
Date:5/20/2010

"xn-person">Andrew R. Haas, M.D., Ph.D., Hospital of the University of Pennsylvania, and investigator on JX-594 Phase 1 trial.

This open-label, dose-escalation study was completed at four sites in the United States and Canada.  A total of 23 patients with solid tumors refractory to standard therapy were enrolled.  Patients received a single treatment at one of five dose levels, with follow-up at periodic intervals.  Six out of eight patients in the higher-dose cohorts evaluable to date (cohorts 3, 4, 5) exhibited disease control as defined by stable disease by RECIST (Response Evaluation Criteria in Solid Tumors) criteria and/or Choi (necrotic) response.  Two out of six patients in the low dose cohorts exhibited disease control (RECIST stable disease) but no responses.  The primary endpoints of the trial included safety and determination of the maximum tolerated dose given through intravenous administration.  No serious adverse events related to JX-594 therapy were reported and no dose-limiting toxicities were reported.  A biomarker analysis further strengthened the finding of dose-dependent replication in tumors following IV administration.

About JX-594

JX-594, currently in Phase 2 clinical trials for liver cancer, is a cancer biotherapeutic product from a proprietary breakthrough class of targeted and armed oncolytic and immunotherapeutic poxviruses.  Tumor destruction and safety was shown in patients with diverse cancer types in three Phase 1 trials; treated patients were end-stage and had no effective therapies available.  JX-594 multiplies selectively within cancer cells, leading to their destruction.  These newly created copies of JX-594 are then released and are able to infect and eradicate other tumor cells
'/>"/>

SOURCE Jennerex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Jennerex Appoints Bob Ingram Special Advisor and Hires Marty Glick as EVP, Corporate Strategy
2. Jennerex Completes $8.3 Million Series B Financing and Appoints Dr. Cal Stiller as Director
3. Jennerex Appoints Samantha Miller as Vice President of Corporate Development
4. Nature Reviews Publishes Article About Jennerexs Multi-Mechanistic Cancer Therapeutic
5. Jennerex Closes $5 Million First Tranche of Series C Financing
6. Jennerex Completes Over-Subscribed Series C Financing for Aggregate Gross Proceeds of Over $5.5 Million
7. Jennerex Adds Industry Veteran Paul Cleveland to Board of Directors
8. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
9. QMed, Inc. Reports July Medicare SNP Enrollments
10. Phlo Affiliate Reports Expanded Coverage to Oregon Border
11. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... La Jolla, CA (PRWEB) July 23, 2014 ... adipose stem cell therapy in the US aimed at ... today announced their newest clinical study for Parkinson’s disease. ... and efficacy of stem cell therapy are paramount when ... , This clinical study makes stem cell therapy accessible ...
(Date:7/23/2014)... July 23, 2014 ... of Trendlines Agtech , announced it has ... Israel,s leading agricultural thermoplastics applications companies. ... Valentis,s technology combines nanocrystalline cellulose (NCC), a biodegradable, ... additional nanoparticles to produce highly improved polymeric films. ...
(Date:7/23/2014)... (PRWEB) July 23, 2014 DuPont Pioneer ... business as vice president of Agricultural Biotechnology (ABT), effective ... where he served most recently as president, chief executive ... and business leadership in the seed and crop protection ... Paul E. Schickler , president of DuPont Pioneer. ...
(Date:7/23/2014)... , July 23, 2014 /PRNewswire/ - BioAmber ... biotechnology company producing sustainable chemicals, today announced that the ... full their option to purchase an additional 420,000 ... price of $12.00 per share, less underwriting discounts ... underwritten public offering of 2,800,000 shares of common ...
Breaking Biology Technology:StemGenex® Gives Hope to Parkinson’s Patients through New Stem Cell Clinical Study 2StemGenex® Gives Hope to Parkinson’s Patients through New Stem Cell Clinical Study 3Valentis Nanotech Signs MOU to Integrate Technology in Thermoplastics Production 2DuPont Pioneer Names Neal Gutterson to Lead Agricultural Biotechnology 2DuPont Pioneer Names Neal Gutterson to Lead Agricultural Biotechnology 3BioAmber announces exercise in full of underwriters' option in connection with previously priced follow-on offering 2BioAmber announces exercise in full of underwriters' option in connection with previously priced follow-on offering 3
... thermal analysis equipment market is poised to exceed $539 million by ... are few lucrative areas that are expected to drive the industry,s ... ... CA (PRWEB) November 10, 2008 -- Economic trends, mergers & acquisitions ...
... CriticalMix Drug Delivery Technology and own Pipeline ... ... England, November 10 Critical,Pharmaceuticals, the speciality pharmaceuticals company, today ... totalling,GBP650,000. Based on the company,s success in developing its unique,CriticalMix ...
... electric power generator able to produce alternating current through ... encapsulated in a flexible plastic substrate with two ends ... generator is the fourth generation of devices designed to ... zinc oxide structures to harvest mechanical energy from the ...
Cached Biology Technology:Calorimeters and Thermal Analysis Equipment Market to Exceed $539 Million by 2012, According to New Report by Global Industry Analysts 2Calorimeters and Thermal Analysis Equipment Market to Exceed $539 Million by 2012, According to New Report by Global Industry Analysts 3Critical Pharmaceuticals Raise GBP650K 2Critical Pharmaceuticals Raise GBP650K 3New small-scale generator produces alternating current by stretching zinc oxide wires 2New small-scale generator produces alternating current by stretching zinc oxide wires 3
(Date:7/23/2014)... membrane degradation and blood-brain barrier damage appear ... brain functioning. Matrix metalloproteinase-9 is able to ... membrane around cerebral blood vessels and to ... Hou and colleagues from the First Affiliated ... University, China induced cerebral infarction in stroke-prone ...
(Date:7/23/2014)... by many studies, but the precise mechanism remains ... Neural Regeneration Research (Vol. 9, No. 11, ... Hospital Affiliated to Tongji Medical College, Huazhong University ... preconditioning in rats by simulating a transient ischemic ... effect of ischemic preconditioning. Researchers discovered that the ...
(Date:7/23/2014)... brain is important for encoding environment inputs ... are unclear. Dr. Zhouyan Feng and co-workers ... of hippocampal neurons in rats using microelectrode ... neuronal responses. Somatosensory stimulation, in the form ... into theta rhythm-dominated waveforms, decreased the spike ...
Breaking Biology News(10 mins):
... NY -- Think of the smell of an orange, a lemon, ... sweetness. And yet each fresh, bright scent is distinguishable from ... chemical compounds. How, then does the brain tell them apart? ... chemical signature as a particular scent? Researchers at ...
... at the University of Saskatchewan have discovered new potential ... buckthorn, according to a new study published today in ... showed that these fruits were nutrient-rich and that the ... for fruit growers in Saskatchewan as these results add ...
... ability of invasive plants to rapidly adapt to local climates -- ... in how quickly they spread. According to new research published ... is rapid evolution -- as much as resistance to local pests ... northern Ontario. "The ability of invasive species to rapidly adapt ...
Cached Biology News:Neuron 'claws' in the brain enable flies to distinguish 1 scent from another 2New potential for nutrient-rich prairie fruits 2Adaptability to local climate helps invasive species thrive 2
BD BioCoat Matrigel Matrix 35 mm Culture Dishes Coating : BD MatrigelTM Basement Membrane Matrix ,Surface : ECM/attachment factors ,Surface area : 9.6 cm2 ,Dim nominal : 35 mm x 10 mm ,Vo...
BD BioCoat Fibronectin 35 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of human fibronectin....
... Mouse Antibody to Human Cytokeratin TYPE ... Basic (Type II) keratins. Including epidermal cell ... at 58kD, 65kD and 67kD. Broad keratin ... oesophagus and cornea. Immunogen: ...
BD BioCoat Fibronectin 150 mm Culture Dishes...
Biology Products: